Advances in Pharmacogenomic Studies
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biologics and Biosimilars".
Deadline for manuscript submissions: 31 May 2024 | Viewed by 2049
Special Issue Editor
Interests: pharmacogenomics; toxicogenomics; personalized medicine; polymorphisms; drug variability
Special Issue Information
Dear Colleagues,
Pharmacogenomics (PGx) is a field of pharmacology that addresses how genetic factors contribute to the body’s response to given medications. This informs prescribing decisions and facilitates the tailoring of patient-specific drug regimens, thus improving clinical responses. Today, PGx is a well-stablished discipline in several developed countries with some clinical applications, but it is considered emergent in developing countries, and has almost no applications in undeveloped countries. This illustrates unequal development in this important field, which is an issue in many countries where this discipline could prove cost-effective or even cost-saving. Since the first publication of the term “pharmacogenetics”, which was coined by Friedrich Vogel in 1959, advances in this field have helped unravel the “mysteries” of variable responses to the same medications, and the role of ethnicity in this disparity.
This Special Issue addresses the current state of pharmacogenomics, precision medicine approaches to improving drug therapies, and challenges that must be overcome to enable their clinical application. Updated research on PGx and its clinical applications is required. To this end, this Special Issue encourages researchers to submit up-to-date original research, meta-analyses, systematic reviews, case reports, clinical trials, and specific reviews on this topic.
Dr. Luis Abel Quiñones
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pharmacogenomics
- pharmacogenetics
- precision medicine
- personalized medicine
- polymorphisms
- drug variability
